Diabetic macular edema and diabetic macular ischemia
Diabetic macular edema and diabetic macular ischemia are complications of diabetic retinopathy.
Search
Positive results Diabetic Macular Ischemia treatment
HORNBILL Phase I/II study shows positive results for potentially first ever Diabetic Macular Ischemia treatment
Neovascular AMD (wet AMD)
Neovascular AMD (or wet AMD) is a severe form of advanced age-related macular degeneration that can lead to irreversible vision loss if untreated
Geographic Atrophy
Geographic atrophy (GA) is an advanced and severe form of dry age-related macular degeneration (AMD) that progresses slowly but can lead to permanent vision loss.
ACCESSIBLE_diabetic_macular_edema_and_diabetic_macular_ischemia
Diabetic_macular_edema_and_diabetic_macular-ischemia
Diabetic_macular_edema_and_diabetic_macular-ischemia.pdf
Retinal Health Research
Our research is targeting key mechanisms in the pathogenesis of retinal diseases – vascular dysfunction, neuronal dysfunction and neuronal inflammation.
Diabetic Retinopathy
Diabetic retinopathy affects 1 in 3 people with diabetes and is the leading cause of vision loss in adults of working age.
Eyes on Retina. The Podcast
Hear from experts and people living with retinal diseases such as wet age-related macular degeneration (AMD), stargardt disease and diabetic retinopathy.
Partnering in Retinal Health
Our partnering interests in retinal diseases offer opportunities for collaboration to complement our pipeline and advance treatment and delivery.
discontinuation-bi-1467335-diabetic-retinopathy
The discontinuation of the development of BI 1467335 in diabetic retinopathy has been announced
Retinal Health
Human Pharma Clinical Pipeline Retinal Health therapeutic area
Thinking differently could eradicate some areas of retinal disease
Retinal disease could be eradicated by thinking differently. Degenerative eye conditions can be cured with a patient-first approach, says Dr Victor Chong.
Retinal health: All eyes on vision loss
Discover how we want to prevent vision loss caused by diabetic retinopathy and other retinal diseases
Partnership to Develop Urea Cycle Disorders Therapy
Boehringer Ingelheim Partners with Thoeris to Investigate a Novel Approach to Treat Urea Cycle Disorders
Phase 1 start of treatment for Geographic Atrophy patients
Boehringer initiates Phase 1 evaluation of BI 771716 a treatment for preserving vision of people living with geographic atrophy (GA)
Nurjanahs Story
Nurjanah went from a sporty young woman to someone who no longer had the energy to do simple, everyday tasks. She was diagnosed with scleroderma.
Geographic Atrophy treatment to move to Phase II
Geographic Atrophy treatment BI 771716 to move to Phase II, following positive Phase I results